Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adimab In Discovery Pacts with Biogen, Novo Nordisk | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adimab In Discovery Pacts with Biogen, Novo Nordisk

To use discovery platform to identify fully human antibodies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adimab has entered separate discovery collaborations with Biogen Idec and Novo Nordisk. Adimab will use its platform to identify fully human antibodies against two targets selected by Biogen and two from Novo Nordisk. Both Biogen and Novo Nordisk have the option to commercialize antibodies generated from the collaborations. Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales. Financial terms were not disclosed.

“Adimab is increasingly recognized as the premier antibody discovery technology in the industry,” said Tillman Gerngross, Adimab’s chief executive officer and co-founder. “Our partners are looking for technologies that improve the lead discovery process and enhance their ability to quickly move novel antibodies into the clinic. Our technology is simply faster, dramatically reduces the risk of development failures, and generates higher quality leads even against challenging targets; in fact many of our partners come to us with targets that have failed using traditional phage display approaches.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics